Wall Street brokerages forecast that BioScrip Inc (NASDAQ:BIOS) will report earnings of ($0.10) per share for the current fiscal quarter, according to Zacks Investment Research. Three analysts have made estimates for BioScrip’s earnings, with estimates ranging from ($0.11) to ($0.10). BioScrip reported earnings of ($0.11) per share during the same quarter last year, which suggests a positive year-over-year growth rate of 9.1%. The firm is scheduled to issue its next earnings report on Tuesday, August 14th.
On average, analysts expect that BioScrip will report full year earnings of ($0.31) per share for the current financial year, with EPS estimates ranging from ($0.32) to ($0.29). For the next year, analysts forecast that the business will report earnings of ($0.14) per share, with EPS estimates ranging from ($0.18) to ($0.11). Zacks’ EPS calculations are a mean average based on a survey of research analysts that cover BioScrip.
BioScrip (NASDAQ:BIOS) last issued its earnings results on Thursday, May 10th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.11) by ($0.01). The firm had revenue of $168.60 million for the quarter, compared to the consensus estimate of $164.72 million. The business’s revenue for the quarter was down 22.6% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.18) earnings per share.
A number of equities research analysts have recently issued reports on BIOS shares. SunTrust Banks reaffirmed a “buy” rating and issued a $3.25 target price on shares of BioScrip in a report on Thursday, March 8th. Craig Hallum reaffirmed a “buy” rating and issued a $3.50 target price on shares of BioScrip in a report on Thursday, March 8th. BidaskClub raised shares of BioScrip from a “hold” rating to a “buy” rating in a report on Saturday, March 3rd. Finally, Zacks Investment Research raised shares of BioScrip from a “sell” rating to a “hold” rating in a report on Tuesday, May 15th. Three analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $3.45.
Shares of BIOS stock traded down $0.01 on Friday, reaching $2.68. The stock had a trading volume of 47,543 shares, compared to its average volume of 464,342. The company has a debt-to-equity ratio of -4.79, a quick ratio of 1.30 and a current ratio of 1.70. The stock has a market cap of $325.00 million, a price-to-earnings ratio of -6.02 and a beta of 0.08. BioScrip has a 12 month low of $1.80 and a 12 month high of $3.39.
Hedge funds have recently modified their holdings of the company. Millennium Management LLC raised its holdings in BioScrip by 334.4% in the 1st quarter. Millennium Management LLC now owns 2,425,782 shares of the company’s stock valued at $5,967,000 after acquiring an additional 1,867,415 shares during the period. Royce & Associates LP raised its holdings in BioScrip by 942.6% in the 4th quarter. Royce & Associates LP now owns 1,824,500 shares of the company’s stock valued at $5,309,000 after acquiring an additional 1,649,500 shares during the period. BlackRock Inc. raised its holdings in BioScrip by 10.2% in the 4th quarter. BlackRock Inc. now owns 6,584,105 shares of the company’s stock valued at $19,161,000 after acquiring an additional 611,302 shares during the period. Dimensional Fund Advisors LP raised its holdings in BioScrip by 53.8% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,364,659 shares of the company’s stock valued at $3,357,000 after acquiring an additional 477,611 shares during the period. Finally, Venor Capital Management LP raised its holdings in BioScrip by 3.1% in the 1st quarter. Venor Capital Management LP now owns 14,651,292 shares of the company’s stock valued at $36,042,000 after acquiring an additional 443,300 shares during the period. 85.46% of the stock is currently owned by institutional investors.
BioScrip, Inc provides infusion solutions in the United States. It engages in the preparation, delivery, administration, and clinical monitoring of pharmaceutical treatments that are administered to a patient through intravenous, subcutaneous, intramuscular, intra-spinal, and enteral methods. The company is primarily involved in the intravenous administration of medications to treat a range of acute and chronic conditions, such as infections, nutritional deficiencies, immunologic and neurologic disorders, cancer, pain, and palliative care.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BioScrip Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip and related companies with MarketBeat.com's FREE daily email newsletter.